Duloxetine

A controlled study on the treatment of depression with duloxetine and paroxetine

度洛西汀与帕罗西汀治疗抑郁症对照研究

Duloxetine for the treatment of stress urinary incontinence in women : An integrated analysis of safety

关于度洛西汀治疗妇女压力性尿失禁安全性的整合分析

Development in Synthesis Research of Duloxetine Hydrochloride ( To be Continued )

盐酸度洛西汀的合成研究进展（待续）

Clinical Research of Duloxetine in Primary Headache with Depression and Anxiety

盐酸度洛西汀治疗原发性头痛伴抑郁焦虑症状的临床研究

Clinical study on combined treatment of thalamic pain using duloxetine and mecobalamin

度洛西汀联用甲钴胺治疗丘脑痛的临床观察

Study on the rat intestinal absorption kinetics of duloxetine hydrochloride in vitro

盐酸度洛西汀大鼠离体肠吸收动力学

Comparative Study between Duloxetine and Fluoxetine in the Treatment of First Episode Depression

度洛西汀与氟西汀治疗首发抑郁症对照研究首发抑郁症患者多导睡眠图的对照研究

Comparison study of duloxetine and paroxetine in the treatment of depression with generalized anxiety disorder

度洛西汀治疗抑郁焦虑共病的对照研究

Contrast Study of Duloxetine and Clomipramine in Treating the Depression of Alzheimer Disease

度洛西汀与氯丙咪嗪治疗阿尔茨海默病抑郁的对照研究

Efficacy and safety of duloxetine with fluoxetine in the treatment of major depressive disorder

盐酸度洛西汀肠溶胶囊治疗抑郁症的疗效和安全性

Determination of Plasma Concentration of Duloxetine by LC-MS

LC-MS法测定人血浆中度洛西汀的浓度

Clinicians need to know whether duloxetine is effective in patients across a broad range of depressive symptoms and depression severity .

临床医生需要知道，度洛西汀是否对不同抑郁症状及严重程度不同的患者有效。

Duloxetine appears to be less cardiotoxic and is licensed in the US and EU for alleiating DPN .

度洛西汀似乎心脏毒性较小，已在美国和欧洲获得使用许可用于治疗DPN。

The dry HC1 , instead of concentrated HC1 solution , was used in the final salt-formation reaction . The overall recovery of hydrochloride Duloxetine reached 18.4 % , which is higher than that with original process reported in the literature ( 13 % ) .

通过对反应原料的摩尔配比、反应温度、溶剂量以及手性拆分等条件的优化，并在最后产品成盐时用干燥HCl气体取代液体盐酸，使最后产品总收率达到18.4%，高于文献报道的13%。